抗体
试剂盒
多肽
探针
蛋白
组织芯片
产品中心
Product Center
Research Grade Cendakimab
All
TD-HW632016_1.jpg
- Catalog： TD-HW632016
- Clonality： mAb
- Application： Research Grade Biosimilar
- Synonyms： 13C5.5, ABT-308, RPC-4046, CAS: 2151032-62-9
-
规格：
1mg
-
价格：
¥询价
定制服务咨询
Research Grade Cendakimab
| Catalog No. | TD-HW632016 |
|---|---|
| Species reactivity | Human |
| Applications | Research Grade Biosimilar |
| Host species | Humanized |
| Isotype | IgG1-kappa |
| Expression system | Mammalian Cells |
| Species | Human |
| Clonality | Monoclonal |
| Target | IL13, NC30, Interleukin-13, IL-13 |
| Endotoxin level | Please contact with the lab for this information. |
| Purity | >95% as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P35225 |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names | 13C5.5, ABT-308, RPC-4046, CAS: 2151032-62-9 |
| Background | Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|
|
Detects Human IL13 in indirect ELISAs. |